The privately owned IRBM Group today represents a diversified preclinical drug discovery company that provides integrated solutions from screening to preclinical candidate selection within the biotech and pharmaceutical sector. IRBM has developed over the years a strong global network of customers and collaborations with big-pharma, not-for-profit and academic institutions. The company was created in 2009 as a spin-off of Merck Research Laboratories, Italy. IRBM industrial background ensures streamlined and optimized processes resulting in efficiency, speed and quality of our deliverables.
IRBM currently employs 250 scientists with extensive drug discovery experience and more than half qualified to MSc/PhD.
IRBM operates a hybrid business model having proprietary drug discovery programs and offering drug discovery services.